{"id":45300,"date":"2026-07-27T16:00:00","date_gmt":"2026-07-27T14:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=31df4737c4168e376a392c06c317981f"},"modified":"2026-07-27T16:00:00","modified_gmt":"2026-07-27T14:00:00","slug":"astrazeneca-results-h1-and-q2-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=45300","title":{"rendered":"AstraZeneca results: H1 and Q2 2026"},"content":{"rendered":"<p>\n<b>Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030<\/b><\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260726929817\/en\/2301168\/5\/original.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260726929817\/en\/2301168\/22\/original.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260726929817\/en\/2301168\/5\/original.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260726929817\/en\/2301168\/21\/original.jpg\" \/><\/a><p>CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca:<\/p><p>\nRevenue and EPS summary<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwtopsingle bwpadl0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>H1 2026<\/b><\/p><\/td><td class=\"bwtopsingle bwpadl0\" colspan=\"2\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>% Change<\/b><\/p><\/td><td class=\"bwtopsingle bwpadl0 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Q2 2026<\/b><\/p><\/td><td class=\"bwtopsingle bwpadl0 bwrowaltcolor1\" colspan=\"2\" rowspan=\"1\"><p class=\"bwalignc bwcellpmargin\">\n<b>% Change<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>$m<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Actual<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>CER<sup>1<\/sup><\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>$m<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Actual<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>CER<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>- Product Sales<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>28,896<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>8<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>5<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>14,510<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>5<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>4<\/i><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>- Alliance Revenue<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>1,699<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>31<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>29<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>874<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>34<\/i><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<i>33<\/i><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nProduct Revenue<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n30,595<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n9<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n15,384<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nCollaboration Revenue<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n77<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(6)<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(9)<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\nn\/m<\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\nn\/m<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Total Revenue<\/b><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>30,672<\/b><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>9<\/b><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>6<\/b><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>15,384<\/b><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>6<\/b><\/p><\/td><td class=\"bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>5<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Reported EPS ($)<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>3.60<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>4<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>3<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>1.61<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>2<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>(2)<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth28\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Core<\/b><sup>2<\/sup> <b>EPS<sup> <\/sup>($)<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>5.21<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>12<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>11<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>2.63<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>21<\/b><\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwpadb3 bwrowaltcolor1 bwwidth12\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>18<\/b><\/p><\/td><\/tr>\n<\/table><p>\n<span class=\"bwuline\">Key performance elements for H1 2026<\/span><\/p><p>\n(Growth numbers at constant exchange rates)<\/p><ul class=\"bwlistdisc\">\n<li>\nTotal Revenue up 6%, with double-digit growth in Oncology and Rare Disease offsetting headwinds from <i>Farxiga<\/i> US loss of exclusivity and China volume-based procurement<\/li>\n<li>\nCore Operating profit and Core EPS increased 11%<\/li>\n<li>\nInterim dividend increased 3 cents to $1.06 per share (79.5 pence, 10.32 SEK)<\/li>\n<li>\n30 approvals in major regions since Q4 2025 results<\/li>\n<\/ul><p>\n<span class=\"bwuline\">Pascal Soriot, Chief Executive Officer, AstraZeneca, said:<\/span><\/p><p>\n\"In the first half we saw strong performance and continued pipeline delivery, including six key positive Phase III programmes and eight first approvals in major markets, including in the US for Baxfendy, our first-in-class medicine for hypertension.<\/p><p>\nWhile we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks. We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months.<\/p><p>\nWe continue to invest at pace in our transformative technologies, and in our commercial execution to bring our innovative medicines to patients around the globe and drive growth beyond 2030.\"<\/p><p>\n<span class=\"bwuline\">Guidance<\/span><\/p><p>\nAstraZeneca reconfirms Total Revenue and Core EPS guidance<sup>3<\/sup> for FY 2026 at CER, based on the average foreign exchange rates through 2025.<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignc\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Total Revenue<\/b> is expected to increase by a <b>mid-to<\/b>-<b>high single-digit<\/b> percentage<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>Core EPS<\/b> is expected to increase by a <b>low double-digit<\/b> percentage<\/p><\/td><\/tr>\n<\/table><p>\nThe Core Tax rate is expected to be between 18-22%<\/p><p>\nIf foreign exchange rates for July 2026 to December 2026 were to remain at the average rates seen in June 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact (unchanged) compared to the performance at CER, and Core EPS growth would be broadly similar (unchanged) to the growth at CER.<\/p><p>\nResults highlights<\/p><p>\nTable 1: Milestones achieved since the prior results announcement<\/p><p>\nPhase III and other registrational data readouts<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Medicine<\/b><\/p><\/td><td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Trial<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Indication<\/b><\/p><\/td><td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Event<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nVOLGA<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nMIBC not candidates for cisplatin<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPrimary endpoint met<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nEMERALD-2<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nAdjuvant HCC<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPrimary endpoint not met<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNILE<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n1L bladder cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPrimary endpoint met<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nsone-ve<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nCLARITY-Gastric01<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n2L+ Cldn18.2+ gastric\/GEJ cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPrimary endpoint met<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Wainua<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nCARDIO-TTRansform<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nATTR-CM<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPrimary endpoint not met<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Ultomiris<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTMA-313<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHSCT-TMA (adults)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPrimary endpoint not met<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Ultomiris<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nALXN1210-MG-319<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\ngMG (paediatric)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPrimary endpoint met<\/p><\/td><\/tr>\n<\/table><p>\nRegulatory approvals<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Medicine<\/b><\/p><\/td><td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Trial<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Indication<\/b><\/p><\/td><td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Region<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Calquence<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nAMPLIFY<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n1L CLL (fixed duration)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nJP<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Datroway<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTROPION-Breast02<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n1L TNBC for patients where immunotherapy is not an option<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUS<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Enhertu<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nDESTINY-Breast05<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHigh-risk HER2+ early breast cancer (post-neoadjuvant)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUS<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Enhertu<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nDESTINY-Breast11<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNeoadjuvant HER2+ Stage II or III breast cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUS<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Enhertu<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nDESTINY-PanTumor02 \/ DESTINY-Lung01 \/ DESTINY-CRC02<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHER2-positive solid tumours<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nEU<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Etcamah <\/i>(camizestrant)<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nSERENA-6<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>ESR1<\/i>m HR+ HER2- 1L locally advanced or metastatic\n<br\/>breast cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nEU, JP<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPOTOMAC<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNMIBC<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUS<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Imfinzi<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nMATTERHORN<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nResectable gastric\/GEJ cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nJP<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Orphathys<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNCT04923932<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n3L+ MET+ gastric\/GEJ cancer<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nCN<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Truqap<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nCAPItello-281<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nPTEN-deficient mHSPC<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUS<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Baxfendy<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nBaxHTN<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHypertension<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUS<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Fasenra<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNATRON<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHypereosinophilic syndrome<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUS, EU, JP, CN<\/p><\/td><\/tr>\n<\/table><p>\nRegulatory submissions or acceptances* in major regions<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Medicine<\/b><\/p><\/td><td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Trial<\/b><\/p><\/td><td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Indication<\/b><\/p><\/td><td class=\"bwtopsingle bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<b>Region<\/b><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Baxfendy<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nBaxHTN \/ Bax24 \/ BaxAsia<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHypertension<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nJP<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\ntozorakimab<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOBERON \/ TITANIA \/ MIRANDA \/ PROSPERO<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nCOPD<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nEU, CN<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>Ultomiris<\/i><\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nI CAN<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nIgAN<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nUS, JP<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nefzimfotase alfa<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth21\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nMULBERRY \/ CHESTNUT \/ HICKORY<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth37\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nHPP<\/p><\/td><td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth27\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nJP<\/p><\/td><\/tr>\n<\/table><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>* US, EU and China regulatory entries in this table denote filing acceptance<\/i><\/p><\/td><\/tr>\n<\/table><p>\n<span class=\"bwuline\">Other pipeline updates<\/span><\/p><p>\nFor recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix document in the financial results section of the AstraZeneca investor relations website: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Finvestor-relations.html&amp;esheet=54577164&amp;newsitemid=20260726929817&amp;lan=en-US&amp;anchor=www.astrazeneca.com%2Finvestor-relations.html&amp;index=1&amp;md5=ee4ac80208da062f93579ea2c0eb1008\" rel=\"nofollow\" shape=\"rect\">www.astrazeneca.com\/investor-relations.html<\/a><\/p><p>\nTable 2: Key elements of financial performance: Q2 2026<\/p><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwtopsingle bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nFor the<b> quarter<\/b><\/p><\/td><td class=\"bwtopsingle bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwtopsingle bwpadl0 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Reported<\/b><\/p><\/td><td class=\"bwtopsingle bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwtopsingle bwpadl0 bwvertalignb bwpadr0 bwalignc\" colspan=\"3\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>Change<\/b><\/p><\/td><td class=\"bwtopsingle bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwtopsingle bwpadl0 bwrowaltcolor1 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Core<\/b><\/p><\/td><td class=\"bwtopsingle bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwtopsingle bwpadl0 bwrowaltcolor1 bwvertalignb bwpadr0 bwalignc\" colspan=\"3\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignc\">\n<b>Change<\/b><\/p><\/td><td class=\"bwtopsingle bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwtopsingle bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwtopsingle bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nended 30 June<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>$m<\/b><\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Act<\/b><\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>CER<\/b><\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>$m<\/b><\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>Act<\/b><\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n<b>CER<\/b><\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nProduct Revenue<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n15,384<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n15,384<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwalignl bwwidth43\" colspan=\"1\" rowspan=\"1\"><p>\n* See Tables 3, 7, 23, 24 and 25 for further details of Product Revenue, Product Sales and Alliance Revenue<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nCollaboration Revenue<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\nn\/m<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\nn\/m<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\nn\/m<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\nn\/m<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwalignl bwwidth43\" colspan=\"1\" rowspan=\"1\"><p>\n* See Tables 4 and 26 for further details of Collaboration Revenue<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTotal Revenue<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n15,384<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n15,384<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5<\/p><\/td><td class=\"bwsinglebottom bwrowaltcolor1 bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwalignl bwwidth43\" colspan=\"1\" rowspan=\"1\"><p>\n* See Tables 5 and 6 for Total Revenue by Therapy Area and by region<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\" style=\"height:129px;\"><p class=\"bwcellpmargin\">\nGross Margin (%)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\" style=\"height:129px;\"><p class=\"bwalignr bwcellpmargin\">\n84<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\" style=\"height:129px;\"><p class=\"bwalignr bwcellpmargin\">\n+1pp<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\" style=\"height:129px;\"><p class=\"bwalignr bwcellpmargin\">\n-<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\" style=\"height:129px;\"><p class=\"bwalignr bwcellpmargin\">\n84<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\" style=\"height:129px;\"><p class=\"bwalignr bwcellpmargin\">\n+1pp<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\" style=\"height:129px;\"><p class=\"bwalignr bwcellpmargin\">\n+1pp<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\" style=\"height:129px;\"><p class=\"bwcellpmargin\">\n+ Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue\n<br\/>\u2212 Pricing headwinds, including those driven by loss of exclusivity and VBP in China<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nR&amp;D expense<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n4,053<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n14<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n13<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n3,662<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n6<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p>\n* Core R&amp;D: 24% of Total Revenue\n<br\/>+ Increasing number of trials, and patients in those trials\n<br\/>+ Investments in transformative technologies\n<br\/>+ Addition of R&amp;D projects from business development\n<br\/>+ Positive data readouts for high value pipeline opportunities that have ungated large late-stage trials<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nSG&amp;A expense<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5,651<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n16<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n14<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n4,050<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n7<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n4<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p>\n* Core SG&amp;A: 26% of Total Revenue\n<br\/>+ Investment to support ongoing and future launches<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOther operating income and expense<sup>4<\/sup><\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n152<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n92<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n93<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n152<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n&gt;2x<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n&gt;2x<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n+ Various partner milestones<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOperating profit<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n3,164<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(10)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(13)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n5,158<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n12<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n10<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nOperating Margin (%)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n21<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-4pp<\/p><\/td><td class=\"bwsinglebottom bwvertalignb bwpadr0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignr\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-4pp<\/p><\/td><td class=\"bwsinglebottom bwvertalignb bwpadr0 bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignr\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignb bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n34<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwvertalignb bwpadr0 bwwidth1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignr\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+2pp<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwvertalignb bwpadr0 bwwidth1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignr\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwvertalignb bwpadr0 bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n+2pp<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nNet finance expense<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n355<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(4)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(8)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n340<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n13<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n8<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n+ Lower interest income on short-term deposits\n<br\/>\u2212 Reported Net finance expense benefitted from a lower discount unwind on contingent consideration liabilities<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nTax rate (%)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n10<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-11pp<\/p><\/td><td class=\"bwsinglebottom bwpadr0 bwvertalignt bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignr\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-11pp<\/p><\/td><td class=\"bwsinglebottom bwpadr0 bwvertalignt bwwidth2\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignr\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n15<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwpadr0 bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignr\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-6pp<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwpadr0 bwvertalignt bwwidth1\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin bwalignr\">\n\u00a0<\/p><\/td><td class=\"bwsinglebottom bwpadl0 bwrowaltcolor1 bwpadr0 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n-6pp<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u2212 Benefit from adjustments to deferred tax assets, as a result of certain internal legal entity changes.<\/p><p>\n* Variations in the tax rate can be expected between periods<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth15\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\nEPS ($)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n1.61<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n(2)<\/p><\/td><td class=\"bwsinglebottom bwwidth2\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n2.63<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n21<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwpadb3 bwrowaltcolor1 bwvertalignt bwwidth5\" colspan=\"1\" rowspan=\"1\"><p class=\"bwalignr bwcellpmargin\">\n18<\/p><\/td><td class=\"bwrowaltcolor1 bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwsinglebottom bwwidth1\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0 bwwidth43\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<\/table><table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>For dollar values in this table, the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp).<\/i><\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n\u00a0<\/p><\/td><\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\"><p class=\"bwcellpmargin\">\n<i>In the table above, R&amp;D expense, SG&amp;A expense and Net finance expense are displayed as positive numbers. The plus and minus symbols next to comments denote the directional impact of the item being discussed. For example, a plus symbol next to a comment about an R&amp;D item indicates that the item increased R&amp;D expenditure relative to the prior year period.<\/i><\/p><\/td><\/tr>\n<\/table><p>\n<span class=\"bwuline\">Corporate and business development<\/span><\/p><p>\nDizal Pharmaceutical Co\n<br\/>In July 2026, AstraZeneca entered into an exclusive license agreement with Dizal Pharmaceutical Co (Dizal), Ltd for <i>Zegfrovy<\/i> (sunvozertinib), a novel oral irreversible EGFR inhibitor for patients with lung cancer.<\/p><p>\nAstraZeneca will acquire worldwide rights to develop and commercialise <i>Zegfrovy<\/i>, which is approved in the US and China for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.<\/p><p>\nAstraZeneca will make an upfront payment to Dizal of $600m and additional payments of up to $900m upon achievement of specific development, regulatory and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of <i>Zegfrovy<\/i>. The transaction is expected to close in the second half of 2026, subject to customary closing conditions and regulatory clearances.<\/p><p>\nSino Biopharmaceutical\n<br\/>In July 2026, AstraZeneca and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited, entered into an exclusive licence agreement for the development, manufacturing and commercialisation of CTTQ's PDE3\/4 inhibitor, TQC3721, which is being developed for respiratory indications.<\/p><p>\nSino Biopharmaceutical Limited is eligible to receive an upfront payment of $200m, with additional development, regulatory and sales milestones up to $1.9bn, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products.<\/p><p>\nThe agreement is subject to customary closing conditions, including regulatory clearances.<\/p><p>\n<span class=\"bwuline\">Sustainability highlights<\/span><\/p><p>\nIn July 2026, AstraZeneca hosted a call for investors to discuss the latest developments in its Sustainability strategy. A replay of the call is available on <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Finvestor-relations.html&amp;esheet=54577164&amp;newsitemid=20260726929817&amp;lan=en-US&amp;anchor=astrazeneca.com&amp;index=2&amp;md5=a4f01c2a17f3e79bd2f8f37be6f23f8d\" rel=\"nofollow\" shape=\"rect\">astrazeneca.com<\/a>.<\/p><p>\n<span class=\"bwuline\">Reporting calendar<\/span><\/p><p>\nThe Company intends to publish its 9M and Q3 2026 results on 30 October 2026.<\/p><p>\n<span class=\"bwuline\">Conference call<\/span><\/p><p>\nA conference call and webcast for investors and analysts will begin today, 27 July 2026, at 11:45 UK time. Details can be accessed via <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Finvestor-relations.html&amp;esheet=54577164&amp;newsitemid=20260726929817&amp;lan=en-US&amp;anchor=astrazeneca.com&amp;index=3&amp;md5=dab43e6b3f1bb1b7ae66b73f73478f2d\" rel=\"nofollow\" shape=\"rect\">astrazeneca.com<\/a>.<\/p><p>\n<span class=\"bwuline\">Notes<\/span><\/p><ol class=\"bwlistdecimal\">\n<li>\nConstant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2026 vs. 2025. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.\n<br\/>\n<br\/><\/li>\n<li>\nCore financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Tables 10 and 11 in the Financial Performance section of this document.\n<br\/>\n<br\/><\/li>\n<li>\nThe Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the Cautionary statements section regarding forward-looking statements at the end of this announcement.\n<br\/>\n<br\/><\/li>\n<li>\nIncome from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group's financial statements.<\/li>\n<\/ol><p class=\"bwmarginl1\">\nTo read AstraZeneca's H1 &amp; Q2 2026 Financial Results press release in full, read <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2026%2Fh1-and-q2-2026-results.html&amp;esheet=54577164&amp;newsitemid=20260726929817&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=f0d30630e472dfa4fd26fc3949ef6649\" rel=\"nofollow\" shape=\"rect\">here<\/a> .<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nGlobal Media Relations team\n<br\/><a  href=\"mailto:global-mediateam@astrazeneca.com\" rel=\"nofollow\" shape=\"rect\">global-mediateam@astrazeneca.com<\/a><br\/>+44 (0)1223 344 800<\/p>","protected":false},"excerpt":{"rendered":"<p>Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030CAMBRIDGE, England&#8211;(BUSINESS WIRE)&#8211;AstraZeneca:<br \/>\nRevenue and EPS summary<\/p>\n<p>\u00a0<br \/>\nH1 2026<br \/>\n% Change<br \/>\nQ2 2026<br \/>\n% Change<\/p>\n<p>\u00a0<br \/>\n$m<br \/>\nActual<br \/>\nCER1<br \/>\n$m<br \/>\nActual<br \/>\nCER<\/p>\n<p>&#8211; Product&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-45300","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45300"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45300\/revisions"}],"predecessor-version":[{"id":45301,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/45300\/revisions\/45301"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}